| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/07/2010 | CA2729128A1 Benzimidazoles and related analogs as sirtuin modulators |
| 01/07/2010 | CA2729110A1 Isolation of cyclopamine |
| 01/07/2010 | CA2729077A1 Methods and ophthalmic devices used in the treatment of ocular allergies |
| 01/07/2010 | CA2728769A1 Nitrogen heterocycle derivatives as proteasome modulators |
| 01/07/2010 | CA2728762A1 Rna antagonists targeting hsp27 |
| 01/07/2010 | CA2728683A1 Novel phenylpyrazinones as kinase inhibitors |
| 01/07/2010 | CA2728681A1 Adenine receptor ligands |
| 01/07/2010 | CA2728563A1 Use of mifepristone for the treatment of amyotrophic lateral sclerosis |
| 01/07/2010 | CA2728559A1 Cdk modulators |
| 01/07/2010 | CA2728547A1 Solid dosage formulations of telcagepant potassium |
| 01/07/2010 | CA2728492A1 Treatment |
| 01/07/2010 | CA2728328A1 Treatment of antibiotic-resistant bacteria infection |
| 01/07/2010 | CA2728301A1 Vinpocetine and eburnamonine derivatives for promoting bone growth |
| 01/07/2010 | CA2728219A1 Diglycidic ether derivative therapeutics and methods for their use |
| 01/07/2010 | CA2728170A1 A crystalline form of posaconazole |
| 01/07/2010 | CA2727252A1 Isoindolone derivatives as mek kinase inhibitors and methods of use |
| 01/07/2010 | CA2727250A1 Bicyclic heterocycles as mek kinase inhibitors |
| 01/07/2010 | CA2727103A1 Naphthyridinones as aurora kinase inhibitors |
| 01/07/2010 | CA2726999A1 New drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| 01/07/2010 | CA2726221A1 Antiallergic marine biopolymers |
| 01/07/2010 | CA2726040A1 Quinazoline derivatives |
| 01/07/2010 | CA2724740A1 Formulations of 5-fluorocytosine and uses thereof |
| 01/07/2010 | CA2633585A1 Treatments for any and all mental/brain neuron/spinal cord illness |
| 01/06/2010 | EP2141236A1 Process for production of lipstatin and microorganisms therefore |
| 01/06/2010 | EP2141234A1 Short Interfering RNA (siRNA) Analogues |
| 01/06/2010 | EP2141233A1 Antisense design |
| 01/06/2010 | EP2141231A1 METHOD FOR INHIBITION OF SIGNALING THROUGH ErbB2, SIGNALING INHIBITOR FOR USE IN THE METHOD, AND USE OF THE SIGNALING INHIBITOR |
| 01/06/2010 | EP2141172A1 Cyclopropyl polymerase inhibitors |
| 01/06/2010 | EP2141171A1 Pyridine derivative substituted with heterocycle and phosphonoamino and antifungal agent containing the same |
| 01/06/2010 | EP2141168A1 Heteroaryl derivatives |
| 01/06/2010 | EP2141166A1 Adenine receptor ligands |
| 01/06/2010 | EP2141164A1 New 1,2,4-triazine derivatives and biological applications thereof |
| 01/06/2010 | EP2141163A1 Substituted thiazolidinones, their production and utilisation as medicine |
| 01/06/2010 | EP2141162A1 3-(n-heterocyclyl)-pyrrolidinyl-phenyl-oxazolidinones as antibacterial agents |
| 01/06/2010 | EP2141161A1 3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents |
| 01/06/2010 | EP2141160A1 Ground crystal of olmesartan medoxomil |
| 01/06/2010 | EP2141159A1 A Crystalline form of posaconazole |
| 01/06/2010 | EP2141155A1 Prophylactic and/or therapeutic agent for hyperlipemia |
| 01/06/2010 | EP2141154A1 Oxazolidinone derivative having inhibitory activity on 11 -hydroxysteroid dehydrogenase type i |
| 01/06/2010 | EP2141150A1 Bicyclic compound and pharmaceutical use thereof |
| 01/06/2010 | EP2141148A1 Indole derivative having cpla2 inhibitory activity, use of the same and method for producing the same |
| 01/06/2010 | EP2141147A1 Ornithine derivative |
| 01/06/2010 | EP2141146A1 Calcilytic compounds |
| 01/06/2010 | EP2140884A1 A vaccine preventing and/or treating autoimmune diseases |
| 01/06/2010 | EP2140883A1 Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion |
| 01/06/2010 | EP2140882A1 Agent for treatment of pulmonary disease |
| 01/06/2010 | EP2140879A1 Composition and method for treating cancer using herpes virus |
| 01/06/2010 | EP2140871A1 Suspension for visualization of transparent tissue in eye |
| 01/06/2010 | EP2140870A1 Prompt nucleic acid delivery carrier composition |
| 01/06/2010 | EP2140868A1 Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy |
| 01/06/2010 | EP2140867A1 Pharmaceutical composition |
| 01/06/2010 | EP2140866A1 Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract |
| 01/06/2010 | EP2140865A1 Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
| 01/06/2010 | EP2140864A2 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods |
| 01/06/2010 | EP2140863A1 Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders |
| 01/06/2010 | EP2140862A2 Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods |
| 01/06/2010 | EP2140771A1 Method for stimulating the intestinal flora in infants delivered by caesarean section |
| 01/06/2010 | EP2140268A1 Method for controlling glucose uptake and insulin sensitivity |
| 01/06/2010 | EP2140004A2 Genetic suppression and replacement |
| 01/06/2010 | EP2139994A2 2786, a human aminopeptidase |
| 01/06/2010 | EP2139992A1 A method of modulating the activity of a nucleic acid molecule |
| 01/06/2010 | EP2139913A2 Inducing immune-mediated tumor cell death |
| 01/06/2010 | EP2139908A2 Li-rnai involved li suppression in cancer immunotherapy |
| 01/06/2010 | EP2139899A1 Crystalline forms of topotecan hydrochloride and processes for making the same |
| 01/06/2010 | EP2139897A1 Crystalline and amorphous forms of naltrexone hydrochloride |
| 01/06/2010 | EP2139896A1 Pyrimido [4, 5-d]azepine derivatives as 5-ht2c agonists |
| 01/06/2010 | EP2139894A1 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
| 01/06/2010 | EP2139891A1 4-substituted azaadamantane derivatives and methods of use thereof |
| 01/06/2010 | EP2139887A2 Metalloprotease inhibitors containing a heterocyclic moiety |
| 01/06/2010 | EP2139886A1 Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity |
| 01/06/2010 | EP2139883A2 Hiv-1 protease inhibitors |
| 01/06/2010 | EP2139881A1 Quinolines and their therapeutic use |
| 01/06/2010 | EP2139880A1 Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor |
| 01/06/2010 | EP2139879A1 Quinoline derivatives for the treatment of inflammatory diseases |
| 01/06/2010 | EP2139877A1 Deuterated piperazine derivatives as anti-anginal compounds |
| 01/06/2010 | EP2139876A1 Cathepsin cysteine protease inhibitors |
| 01/06/2010 | EP2139875A2 Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators |
| 01/06/2010 | EP2139872A1 Novel antibiotics |
| 01/06/2010 | EP2139869A2 Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
| 01/06/2010 | EP2139866A2 Crystalline 1-(cyclohexyloxycarbonyloxy) ethyl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate and a process for its preparation |
| 01/06/2010 | EP2139865A1 Solid forms of (e) -1- (4- ( (ir, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl) ethanone oxime |
| 01/06/2010 | EP2139862A1 Cosmetic preparations designed to reduce unsightly cellulite |
| 01/06/2010 | EP2139858A1 Piperidinone carboxamide derivatives as p2x7 modulators |
| 01/06/2010 | EP2139857A1 Sub-type selective azabicycloalkane derivatives |
| 01/06/2010 | EP2139856A1 Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds |
| 01/06/2010 | EP2139855A1 Medicaments useful as potassium channel modulators |
| 01/06/2010 | EP2139854A2 P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
| 01/06/2010 | EP2139851A2 Substituted amide derivatives |
| 01/06/2010 | EP2139850A1 Inhibitors of histone deacetylase |
| 01/06/2010 | EP2139848A1 Deuterium labelled ketamine |
| 01/06/2010 | EP2139847A1 Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies |
| 01/06/2010 | EP2139843A1 Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| 01/06/2010 | EP2139836A1 Perfluoroketone compounds and uses thereof |
| 01/06/2010 | EP2139522A2 Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers |
| 01/06/2010 | EP2139512A1 Ischemic disorder or disease inhibitors |
| 01/06/2010 | EP2139511A1 Pharmaceutical composition comprising a cytokine |
| 01/06/2010 | EP2139496A2 Oligonucleotide compositions for the treatment of alzheimer's disease |
| 01/06/2010 | EP2139495A1 Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints |
| 01/06/2010 | EP2139494A1 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate |
| 01/06/2010 | EP2139492A1 Methods for treating neovascular ocular diseases |